Orotransmucosal drug delivery systems: A review

Journal of Controlled Release

Volumn 140, Issue 1, 2009, Pages 2-11

  Madhav, N V Satheesh ^a   Shakya, Ashok K ^b   Shakya, Pragati ^c   Singh, Kuldeep ^c  

^a Dehradoon Institute of Technology   (India)

^b AL AHLIYYA AMMAN UNIVERSITY   (Jordan)

^c INTEGRAL UNIVERSITY   (India)

Author keywords

Drug delivery; Paracellular; Soft palate; Transcellular; Transmucosal

Indexed keywords

ABSORPTION RATES; ALTERNATIVE METHODS; BLOOD SUPPLY; DELIVERY ROUTES; DEVELOPMENT PROCESS; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HIGH COSTS; MUCOSAL SURFACE; ORAL MUCOSA; PARACELLULAR; PHYSICOCHEMICAL PROPERTY; RESIDENCE TIME; SOFT PALATE; SYSTEMIC CIRCULATION; TRANSCELLULAR; TRANSMUCOSAL;

ABSORPTION; BIOCHEMISTRY; DRUG DELIVERY;

DRUG PRODUCTS;

AMIKACIN; ANALGESIC AGENT; ATRIDOX; BILE SALT; BUPRENORPHINE; CARBOMER; CHELATING AGENT; CHITOSAN; CYDOT; DOXYCYCLINE; EDETATE SODIUM; ETOMIDATE; FENTANYL; FENTANYL CITRATE; GENTAMICIN; GLYCERYL TRINITRATE; INSULIN; ISOCARD SPRAY; ISOSORBIDE DINITRATE; LINITRAL SPRAY; MELATONIN; METRONIDAZOLE; MIDAZOLAM; MORPHINE; NANOPARTICLE; NICOTINE; NICOTINE GUM; NIFEDIPINE; PEPTIDE DERIVATIVE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; SCOPOLAMINE; SEDATIVE AGENT; SURFACTANT; TEMENTILL; TENGERIN; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHEWING GUM; CIRCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG PENETRATION; ELECTROPHORESIS; EPITHELIUM CELL; FIRST PASS EFFECT; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LOW DRUG DOSE; MOUTH MUCOSA; MUSCLE RIGIDITY; NONHUMAN; PAIN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SUSPENSION; THERMODYNAMICS; VASCULARIZATION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; MOUTH MUCOSA;

EID: 70349829012     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.07.016     Document Type: Review

References (82)

1. Chiappin S., et al. Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin. Chim. Acta 383 (2007) 30-40
2. Semalty A., Semalty M., Singh R., Saraf S.K., and Saraf S. Properties and formulation of oral drug delivery systems of protein and peptides. Ind. J. Pharm. Sci. 69 6 (2007) 741-747
3. R.N. Acharya, J.L. Baker. US20016210699 (2001).
4. Lehr C.M., and Haas J. Developments in the area of bioadhesive drug delivery systems. Expert Opin. Biol. Ther. 2 3 (2002) 287-298
5. Lee J., Kil S., and Choi Y.W. The effect of storage conditions on the permeability of porcine buccal mucosa. Arch. Pharm. Res. 25 4 (2002) 546-549
6. Petelin M., Marjeta S., Stolic Z., and Skaleric U. EPR study of mucoadhesive ointments for delivery of liposomes into the oral mucosa. Int. J. Pharm. 173 (1998) 193-202
7. Wertz P.W., and Squier C.A. Cellular and molecular basis of barrier function in oral epithelium. Crit. Rev. Ther. Drug Carr. Syst. 8 (1991) 237-269
8. Squier C.A., Kremer M.J., Bruskin A., Rose A., and Haley J.D. Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro. Pharm. Res. 16 10 (1999) 1557-1563
9. Ganem Q., Rieg F., and Buri P. Contribution of lipid components to the permeability barrier of oral mucosa. Eur. J. Pharm. Biopharm. 44 2 (1997) 107-120
10. Slomiany B.L., Murty V.L.N., Piotrowski J., and Slomiany A. Salivary mucins in oral mucosal defense. Gen. Pharmacol.: The Vascular System 27 5 (1996) 761-771
11. Bures P., Huang Y., Oral E., and Peppas N.A. Surface modifications and molecular imprinting of polymers in medical and pharmaceutical applications. J. Control. Release 72 1-3 (2001) 25-33
12. Rathbone M., Drummond B., and Tucker I. Oral cavity as a site for systemic drug delivery. Adv. Drug Del. Rev. 13 1 (1994) 1-22
13. Gandhi R.B., and Robinson J.R. Oral cavity as a site for bioadhesive drug delivery. Adv. Drug Del. Rev. 13 1-2 (1994) 43-74
14. Squier C.A., and Wertz P.W. Structure and function of the oral mucosa and implications for drug delivery. In: Rathbone M.J. (Ed). Oral Mucosal Drug Delivery, Vol. 29 (1996), Marcel Dekker, Inc., New York, New York 1-26
15. Harris D., and Robinson J.R. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 81 1 (1992) 1-10
16. Mashru R., Sutariya V., Sankalia M., and Sankalia J. Transbuccal delivery of lamotrigine across porcine buccal mucosa: in vitro determination of routes of buccal transport. J. Pharm. Pharmaceut. Sci. 8 1 (2005) 54-62
17. Edgar W.M. Saliva: its secretion, composition and functions. Br. Dent. J. 172 8 (1992) 305-312
18. Gilles P., Ghazali F.A., and Rathbone J. Systemic oral mucosal drug delivery systems and delivery systems. Oral Mucosal Drug Delivery (1996), Marcel Dekker Inc, New York 241-285
19. Allen A. The gastrointestinal physiology. Salivary, gastric and hepatobiliary secretions. In: Forte J.G. (Ed). Handbook of Physiology, Vol. III Section 6 (1989), American Physiological Society, Bethesda, MD 359-382
20. Norris D.A., Puri N., and Sinko P.J. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 34 2-3 (1998) 135-154
21. Castellanos M.R., Zia H., and Rhodes C.T. Mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm. 19 1 and 2 (1993) 143-194
22. Squier C., and Wertz P. Structure and function of the oral mucosa and implications for drug delivery. In: Rathbone M.J. (Ed). Oral Mucosal Drug Delivery (1996), Marcel Dekker, Inc., New York 1-26
23. Dawes C. Gland size estimation and body mass index improve salivary flow rate assessment. Arch. Oral Biol. 52 5 (2007) 409-410
24. Squier C.A., and Wertz P.W. Permeability and the pathophysiology of oral mucosa. Adv. Drug Deliv. Rev. 12 (1993) 13-24
25. Hakan U., Naldöken S., Ercan M.T., Ulutuncel N., and Araz K. Blood flow to palatal mucosal and skin grafts in mandibular labial vestibuloplasty measured by 133Xe clearance technique. J. Isl. Acad. Sci. 3 1 (1990) 74-77
26. Consuelo D., Jacques Y., Pizzolato G., Guy R., and Falson F. Comparison of the lipid composition of porcine buccal and esophageal permeability barriers. Arch. Oral Biol. 50 12 (2005) 981-987
27. Senel S., Kremer M., Katalin N., and Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr. Pharm. Biotech. 2 2 (2001) 175-186
28. Dowty M.E., Knuth K.E., Irons B.K., et al. Transport of thyrotropinreleasing hormone in rabbit buccal mucosa in vitro. Pharm. Res. 9 9 (1992) 1113-1122
29. Squier C.A., Johnson N.W., and Hackemann M. Structure and function of normal human oralmucosa. In: Dolby A.E. (Ed). Oral Mucosa in Health and Disease (1975), Blackwell Scientific Publications, Oxford 1-112
30. Nusrat A.M., and Bi-Botti C.Y. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J. Control. Release 113 2 (2006) 91-101
31. Lu Y., and Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54 (2002) 675-693
32. Indu K., and Meenakhi K. Ocular preparation: the formulation approach. Drug. Dev. Ind. Pharm. 28 5 (2002) 473-493
33. Giacomo* D., Ylenia Z., and Chiara Z. Review: polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action,safety issues. J. Pharm. Sci. 97 5 (2005) 680
34. Lorenza G.M., Sandra H., and Jeesus V. Inventions designed to enhance drug delivery across pithelial and endothelial cells through the paracellular pathways. Rec. Adv. Drug Deliv. Formul. 2 (2008) 145-147
35. Christina M., Van I., and Anderson J.M. Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 68 (2006) 403-429
36. Zhang H., Zhang J., and Streisan J.B. Oral mucosal drug delivery clinical pharmaco-kinetics and therapeutic applications. Clin. Pharmacokinet. 41 9 (2002) 661-680
37. Nicolazzo J.A., Barry L.R., and Finnin B.C. Buccal penetration enhancers: how do they really work?. J. Control. Release 105 (2005) 1-15
38. Williams A.C., and Barry B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 56 (2004) 603-618
39. Senel S., and Hincal A.A. Drug permeation enhancement via buccal route: possibilities and limitations. J. Control. Release 72 (2001) 133-144
40. Sandri G., Rossi S., Bonferoni M.c., Ferrari F., Zambito Y., Cola G.D., and Caramella C. Buccal penetration enhancement properties of N-trimethyl chitosan: influence of quaternization degree on absorption of a high molecular weight molecule. Int. J. Pharm. 297 (2005) 146-155
41. Jacobsen J. Buccal iontophoretic delivery of atenolol HCl employing a new in vitro threechamber permeation cell. J. Control. Release 70 (2001) 83-95
42. Kost J., Kimmel E., and Enden G. Bubble growth within the skin by rectified diffusion might play a significant role in sonophoresis. J. Control. Release 117 (2007) 246-255
43. Lee-Kim S.J., and Fadvi S. Nasal versus oral midazolam sedation for pediatric dental patients. J. Dent. Child. (Chic) 71 2 (2004) 126-130
44. de Vries M.E., Bodde H.E., Verhoef J.C., and Junginger H.E. Developments in buccal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 8 (1991) 271-303
45. Jaarsma R.L., Gay M.A., Maland L., Badger M.J., Stanley T.H., and Streisand J.B. Oral transmucosal etomidate in human volunteers. Anesth. Analg. 80 (1995) S208
46. Jacobsen J., Christrup L., and Niels-Hennik J. Medicated chewing gums: pros and cons. Am. J. Drug Del. 2 2 (2004) 75-88
47. Streisand J.B., Zhang J., Niu S., McJames S., Natte R., and Pace N.L. Buccal absorption of fentanyl is pH-dependent in dogs. Anesthesiology 82 (1995) 759-764
48. Passalacqua G., Baena-Cagnani C.E., Berardi M., and Canonica G.W. Oral and sublingual immunotherapy in pediatric patients. Curr. Opin. Allergy Clin. Immunol. 3 2 (2003) 1-4
49. Chan K., and Gibaldi M. Effects of first-pass metabolism on metabolite mean residence time determination after oral administration of parent drug. Pharm. Res. 7 (1990) 59-63
50. Schechter N.L., Weisman S.J., Rosenblum M., Bernstein B., and Conard P.L. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics 95 (1995) 335-339
51. Al-Ghananeem A.M., Malkawi A.H., and Crooks P.A. Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech 7 1 (2006) E1-E5
52. Arandia H.Y., and Patil V.U. Glottic closure following large doses of fentanyl. Anesthesiology 66 (1987) 574-575
53. Epstein R.H., Mendel H.G., Witkowski T.A., et al. Preop sedation with Oralet in 2 to 6 year old children. Anesthesiology 83 (1995) A1179
54. Goldstein-Dresner M.C., Davis P.J., Kretchman E., Siewers R.D., Certo N., and Cook D.R. Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine, diazepam, and atropine as preanesthetic medication in children with congenital heart disease. Anesthesiology 74 (1991) 28-33
55. N.V. Satheesh, M.S. Uma Shankar, A. Maurya, A smart bioplate from Lallimantia royalena seeds fro trans-soft palatal delivery, Proceedings of International Conference on Innovations in Drug Delivery from Biomaterial to Devices Held at Naples, Italy 30th September-3rd October.
56. Satheesh N.V., and Uma Shankar M.S. A Smart Flexiplate for Oral Transmucosal Soft Palatal Delivery of Amikacin - Proceedings of the International world PSWC 2007, Held in April 22-23, 2007 at Amsterdam, Netherland (2007)
57. Satheesh N.V., and Uma Shankar M.S. A novel oro-soft palatal platform for transmucosal gentamicin delivery. Proceedings of ICSS Held at Jadavpur University on 13th February 2008 (2008)
58. Heller J., DCW, and Penhale D.W.H. Use of bioerodible polymers. In: Good W.R. (Ed). self-Regulated Drug Delivery Systems PIL. Controlled Release Technology PA vol. 76 (1997) 281-282 Washington, DC ASS
59. Sudhakar Y., Kuotsu K., and Bandyopadhyay A.K. Buccal bioadhesive drug delivery - a promising option for orally less efficient drugs. J. Control. Release 114 1 (2006) 15-40
60. Mizrahi* B., and Domb A.J. Mucoadhesive polymers for delivery of drugs to the oral cavity. Rec. Pat. Drug Del. Formul. 2 2 (2008) 108-119
61. De Vries M.E., Bodde H.E., and Verhoef J.C. Development in buccal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 8 3 (1991) 271-303
62. Avinash N. Science and technology of bioadhesive-based targeted oral delivery systems. Pharma. Technol. 32 11 (2008) 100-121
63. Santos C.A., et al. Correlation of two bioadhesion assays: the everted sac technique and the CAHN microbalance. J. Control. Release 61 (1999) 113-122
64. Salmaso S. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J. Drug Target. 15 6 (2007) 417-427
65. Gilles P., Marie-Jeann M., Assia D., Carlo D., and Dominique D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur. J. Pharm. Biopharm. 44 1 (1997) 25-31
66. Hao J., and Heng P.W.S. Buccal delivery systems. Drug Dev. Ind. Pharm. 29 (2003) 821-832
67. Oliver A., Scholz1, Wolff A., Schumacher A., Libero I., Campisi G., Ciach T., and Velten T. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov. Today 13 5-6 (2008) 247-253
68. Tallury P., Alimohammadi N., and Kalachandra S. Poly(ethylene-co-vinyl acetate) copolymer matrix for delivery of chlorhexidine and acyclovir drugs for use in the oral environment: effect of drug combination, copolymer composition and coating on the drug release rate. Dent. Mater. 23 (2007) 404-409
69. Ciper M., and Bodmeier R. Modified conventional hard gelatin capsules as fast disintegrating dosage form in the oral cavity. Eur. J. Pharm. Biopharm. 62 (2006) 178-184
70. Birudaraj R., et al. Advances in buccal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 22 (2005) 295-330
71. Giannola L.I., et al. Transbuccal tablets of carbamazepine: formulation release and absorption pattern. Int. J. Immunopathol. Pharmacol. 18 (2005) 21-31
72. Ashmitha P., Govender T., and Mackraj I. Using an experimental design to identify and quantify the effects of environment related test parameters on the in vitro mucoadhesivity testing of a propanolol buccal tablet. Drug Dev. Ind. Pharm. 33 7 (2007) 709-716
73. Giannola L.I., et al. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur. J. Pharm. Biopharm. 65 (2007) 238-246
74. Giannola L.I., et al. Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design. Eur. J. Pharm. Biopharm. 67 (2007) 425-433
75. Cooke H.M., and Lynch A. Biorhythms and chronotherapy in cardiovascular disease. Am. J. Health Syst. Pharm. 51 (1994) 2569-2580 29
76. Elliott W.J. Circadian Variation in the Timing of Stroke Onset: a Metaanalysis (1998)
77. M. Krumme, US20060039957 (2006).
78. Al-Waili N.S. Sublingual human insulin for hyperglycaemia in type I diabetes. J. Pak. Med. Assoc. 49 7 (1999) 167-169
79. Modi P., Mihic M., and Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel rapid mist system. Diabetes Metab. Res. Rev. 18 (2002) S38-42
80. Danckwerts M.P. Intraoral drug delivery: a comparative review. Am. J. Drug Deliv. 1 3 (2003) 175-180
81. Shahiwala A., Tushar K., Vyas, and Amiji* M. Nanocarriers for systemic and mucosal vaccine delivery. Rec. Pat. Drug Deliv. Formul. 1 (2007) 1-9
82. Michael A., Suneela P., Manish M., and Praveen M. Matrix- and reservoir-based transmucosal delivery systems: tailoring delivery solutions. technology tools. Am. J. Drug Deliv. 2 3 (2004) 173-192